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VP16 and Ubiquitin: Binding of P-TEFb via Its
Activation Domain and Ubiquitin Facilitates
Elongation of Transcription of Target Genes
pertains to its effects via DNA, we co-expressed the
Lex.VP16 chimera with a plasmid target that contained
six Lex binding sites linked to the minimal HIV-1 long
terminal repeat (LTR) and the chloramphenicol acetyl-
transferase (CAT) reporter gene (pL6CAT) in 293T cells.
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Lex.VP16 fusion protein activated this reporter greaterSan Francisco, California 94115
than 150-fold. Next, we co-expressed this effector and
target with increasing amounts of a mutant dominant-
negative Cdk9 protein (DNCdk9) that contained a substi-Summary
tution of the aspartic acid to asparagine at position 167,
which abolishes its kinase activity and blocks effects ofAcidic or type IIB transcriptional activation domains
P-TEFb [9–11]. Indeed, the DNCdk9 protein decreased(AADs) increase rates of initiation as well as elongation
the transcriptional activity of the Lex.VP16 chimera upof transcription [1]. For the former effects, AADs bind
to 8-fold in a dose-dependent fashion (Figure 1A, right,general transcription factors and larger coactivator
compare bars 2, 3, 4, and 5). Importantly, levels of thecomplexes, which position RNA polymerase II (RNAPII)
Lex.VP16 chimera and endogenous Cdk9 did notat sites of initiation of transcription [2]. For the latter
change with increasing amounts of the mutant DNCdk9effects, their ubiquitylation plays an important role [3].
protein (Figure 1A, Western blotting, compare lanes 2,In this study, this posttranslational modification in-
3, 4, and 5, and see Supplemental Figure S1 availablecreased the binding between a prototypic AAD and
with this article online). These observations indicate thatthe positive transcription elongation factor b (P-TEFb),
the activation of transcription by VP16 depends onwhich contains a C-type cyclin (CycT1, CycT2, or CycK)
P-TEFb.and Cdk9 [4]. By phosphorylating negative elongation
Next, we performed GST capture assays using thefactors and the C-terminal domain of RNAPII, P-TEFb
purified GST.CycT1 chimera and cell lysates expressingmodifies the transcription complex for efficient elon-
Lex or Lex.VP16 fusion proteins to determine that VP16gation and cotranscriptional processing of mRNA [5,
binds P-TEFb [12]. As presented in Figure 1B, left, lanes6]. Indeed, the activation domain of VP16 and ubiquitin
3 and 6, the Lex.VP16 chimera but not Lex bound weaklybound the cyclin boxes and the C terminus in CycT1,
the GST.CycT1 fusion protein. Thus, we hypothesizedrespectively. Moreover, the artificial fusion of ubiquitin
that AADs might bind CycT1 better when ubiquitylated.with VP16 not only increased its activity via DNA and
To this end, we performed ubiquitylation assays on theRNA, which was reflected in increased ratios of elon-
Lex.VP16 fusion protein with the His epitope-taggedgated to initiated transcripts, but rescued the deleteri-
ubiquitin, where ubiquitylated proteins can be separatedous substitution of alanine for phenylalanine at posi-
and purified by Ni-NTA affinity chromatography [13].tion 442 in its AAD. Thus, the ubiquitylation of AADs
Indeed, several forms of the ubiquitylated Lex.VP16 chi-increases their interaction with P-TEFb and augments
mera were detected in 293T cells (Figure 1C, lane 1). Ofrates of elongation of transcription.
interest, as the AAD from VP16 contains no lysines, this
ubiquitylation is on Lex [14]. We conclude that VP16 not
Results and Discussion only activates transcription via P-TEFb and binds its
cyclin subunit, but that Lex.VP16 fusion protein is ubiq-
To confirm that VP16 can bind and recruit P-TEFb to uitylated in vivo.
RNAPII, we compared the activity of this AAD with the To examine effects of this ubiquitylation on the activity
transactivator Tat from HIV-1 and CycT1 when tethered of VP16 in this system, we fused ubiquitin to Lex.VP16
artificially to RNA in transient co-expression assays in (Ub.Lex.VP16) and mutant Lex.VP16F442A (Ub.Lex.
293T cells. Tat binds P-TEFb and activates transcription VP16F442A) chimeras, which contained the substitution
via the transactivation response (TAR) RNA element [7]. of alanine for phenylanine at position 442 that is key for
CycT1 is the predominant cyclin partner of Cdk9 [4]. all transcriptional effects of VP16 [15]. As presented in
Previously, the fusion between VP16 and the regulator Figure 2A, bars 4 and 5, the addition of ubiquitin to the
of virion gene expression (Rev) from HIV-1 (Rev.VP16), Lex.VP16 chimera resulted in 2-fold higher activity on
which binds the stem loop IIB (SLIIB) from the Rev re- pL6CAT without affecting basal levels. Compared to the
sponse element (RRE) RNA stem loop, functioned via Lex.VP16 chimera, the mutant Lex.VP16 F442A fusion
RNA equivalently to Gal.VP16 chimera via DNA [8]. Addi- protein had 80% reduced activity (Figure 2A, compare
tional studies revealed that this genetic system repre- bars 4 and 6). Importantly, the addition of ubiquitin to
sents the recruitment of P-TEFb to the transcription this mutant chimera (Ub.Lex.VP16F442A) increased its
complex [9–11]. Indeed, in this context, VP16 is as potent activity up to 5-fold to the levels of the wild-type
an activator as Tat and CycT1 (Figure 1A, left, compare Lex.VP16 chimera (Figure 2A, compare bars 6 and 7).
bars 2, 3, and 4). To ascertain that this finding also To determine if the addition of ubiquitin affected the
process of elongation of transcription, i.e., increased
the production of long transcripts (LT), we examined*Correspondence: matija@itsa.ucsf.edu
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Figure 1. Structure and Function of VP16 In Vivo
(A) VP16 activates transcription via RNA equivalently to Tat and CycT1 (left), and the activity of VP16 via DNA can be blocked by DNCdk9
protein (right) in 293T cells. Left: Below the bar graph is presented the schematic of the plasmid target pSLIIBCAT, which contains the high-
affinity binding site for Rev. Cotransfected plasmids are presented by plus signs. Levels of activation (fold-activation) were calculated relative
to the co-expression of pSLIIBCAT (0.3 g) and Rev (1.2 g) alone (white bar). Other results are as follows: black bar, pSLIIBCAT and the
Rev.VP16 chimera; gray bars, pSLIIB (0.3 g) and the Rev.Tat or Rev.CycT1 chimeras (all 1.2g). Standard errors of the mean are representative
of two experiments performed in triplicate. Right: Below the bar graph is presented the schematic of the plasmid target pL6CAT, which
contains six palindromic Lex binding sites. Black bars represent the co-expression of the pL6CAT (0.2 g) and the Lex.VP16 chimera (1.0 g)
alone or together with increasing amounts of the DNCdk9 protein (0.5 to 3.0 g). Levels of expression of these two proteins were determined
by Western blotting (below the bar graph). Other experimental conditions and labeling are as in left panels.
(B) The Lex.VP16 chimera binds the GST.CycT1 fusion protein in vitro. Cell lysates expressing Lex or the Lex.VP16 chimera were mixed with
GST or the GST.CycT1 fusion protein. Western blotting with anti-HA antibodies revealed bound proteins (pull-down, lanes 1–6) as well as
proteins present in cell lysates (5%, Lex and Lex.VP16, lanes 8 and 9) (input). GST and GST.CycT1 were produced as described [9] (Coomassie
blue-stained SDS-PAGE, lanes 10 and 11) (input).
(C) The Lex.VP16 chimera is ubiquitylated in cells. The Lex.VP16 and 6xHis.Ub chimeras were co-expressed in 293T cells. Ubiquitylated
Lex.VP16 chimera was recovered by Ni2 affinity chromatography (left, Ni-NTA agarose) and was detected by Western blotting with the anti-
HA antibody (lanes 1–3). 5% input of the Lex.VP16 (right top) and 6xHis.Ub (right bottom) chimeras are present in lanes 4–6.
promoter-proximal short transcripts (ST) and LT in RNA these transcripts reflected accurately nuclear run on
data [17]. With hybrid Lex.VP16, mutant Lex.VP16samples from the same HeLa cells, which were used for
our CAT assays [16]. Previously, we demonstrated that F442A, and mutant Ub.Lex.VP16 F442A proteins, the
Figure 2. Function of Ubiquitylated VP16 via DNA In Vivo
(A) The addition of ubiquitin increases the activity of VP16 and rescues that of the mutant VP16F442A protein via DNA. Depicted proteins and
pL6CAT were co-expressed in HeLa cells. Levels of CAT and fold-activation were measured as in Figure 1.
(B) Short, nonpolyadenylated, arrested transcripts (ST) and long, elongated, polyadenylated transcripts (LT) were detected by RT-PCR (linear
range, 27 cycles). Below agarose gels of amplified DNA fragments is the schematic of primers used to amplify ST and LT. They are drawn
as arrows next to HIV-1 transcripts, which contain TAR at their 5 ends and extend into repeated (R) and 5 untranslated (U5) sequences. ST
and LT measure 59 and 190 nucleotides, respectively. When their intensities are equal, all ST have elongated to LT.
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production of ST was almost identical (Figure 2B, lanes
2 to 4). In sharp contrast, levels of LT were ten times
lower with the mutant Lex.VP16 F442A chimera (Figure
2B, lane 3) and were rescued by the mutant Ub.Lex.VP16
F442A fusion protein to levels of the hybrid Lex.VP16
protein (Figure 2B, compare lanes 2, 3, and 4). These
data indicate that the addition of ubiquitin affects pri-
marily transcriptional elongation. Furthermore, this find-
ing suggests that ubiquitin increases the recruitment of
P-TEFb by VP16.
Next, we performed binding assays using the
GST.CycT1 chimera and different Lex.VP16 fusion pro-
teins that were transcribed and translated using the rab-
bit reticulocyte lysate in vitro. As presented in Figure
3A, lanes 8 and 10, only the LexVP16 chimera but not
Lex alone bound CycT1. Since the mutant Lex.VP16
F442A chimera did not bind CycT1 (Figure 3A, lane 12),
the N-terminal domain of VP16 seems to contribute to
this binding. Interestingly, CycT1 bound the Ub.LexVP16
chimera as well as Cdk9, which represented our positive
control (Figure 3A, compare lanes 11 and 14). Addition-
ally, only the mutant Ub.LexVP16 F442A protein but not
the mutant LexVP16 F442A protein bound CycT1 (Figure
3A, compare lanes 12 and 13). We conclude that VP16
binds CycT1 and that ubiquitin increases this associa-
tion. Furthermore, this binding parallels the results of
our transient expression assays (Figure 2A).
To determine which sequences in CycT1 bind VP16
and/or ubiquitin, we used different GST.CycT1 chimeras
in GST pull-downs (Figures 3B and 3C). The Ub.Lex.
VP16 chimera bound the cyclin boxes at the N terminus
and the C terminus in CycT1 (Figure 3B, lanes 4 and 6).
In sharp contrast, ubiquitin bound only the C terminus
in CycT1 (Figure 3C, lane 5). Thus, as we observed pre-
viously with other AADs, VP16 binds the N terminus
in CycT1 [9–11]. Together, AAD and ubiquitin form a
stronger interaction between these two proteins and
most likely relieve the reported auto-inhibition between
these ends of CycT1 [18].
To confirm the function of ubiquitin in transcriptional
elongation, we also performed RNA tethering assays.
For this purpose, we constructed new chimeras be-
tween VP16 and Rev (Figure 4A). Because the C-terminal
half of its AAD did not contribute to effects of VP16 via
RNA [19], only fusions between Rev and the N terminus
of VP16 were examined. First, although sequences from
positions 413 to 458 of VP16 contain no lysines, we
observed that the Rev.VP16 chimera was ubiquitylated
Figure 3. Binding between Ubiquitylated VP16 and CycT1 In Vitro in 293T cells (Figure 4B, lane 1). Since Rev contains
(A) Ub.Lex.VP16 chimeras bind CycT1 better than Lex.VP16 fusion three lysines, we also expressed a mutant Rev protein
proteins. Lex, Lex.VP16, mutant Ub.Lex.VP16, Lex.VP16 F442A, and (mRev), where these residues were changed to arginines
Ub.Lex.VP16F442A chimeras were expressed from IVT, and binding (Figure 4A). Because Rev and mRev functioned indistin-
assay were performed as described. Lanes 1–7 present binding guishably in the nuclear export assay, these mutations
results with GST, and lanes 8–14 those with the GST.CycT1 chimera.
in Rev do not affect its interactions with SLIIB (dataThe lower left panel presents inputs of GST and the GST.CycT1
not shown). Moreover, the mRev.VP16 chimera was notchimera as in Figure 1. The lower right panel presents 20% of inputs
ubiquitylated in 293T cells (Figure 4B, lane 2). Thisof Lex fusion proteins and Cdk9 (as a control).
(B) The Ub.Lex.VP16 chimera binds cyclin boxes and the C-terminal mRev.VP16 chimera also had 3-fold reduced effects on
sequence in CycT1. Above the Western blotting is the schematic pSLIIBCAT (Figure 4A, compare bars 7 and 8). Next, we
of wild-type and truncated CycT1 proteins. Lane 1 presents 10% expressed the Ub.mRev.VP16, Ub48R63R.mRev.VP16,
of the input of the Ub.Lex.VP16 chimera. The bottom panel presents
and Ub8A44A.mRev.VP16 fusion proteins, which con-inputs of GST fusion proteins.
tained wild-type and mutant ubiquitin proteins at the N(C) The Ub.Lex chimera binds the C-terminal sequence in CycT1.
terminus of the mRev.VP16 chimera, respectively. All ofExperiments and labeling are as in (B).
these Ub.mRev.VP16 fusion proteins had much higher
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Figure 4. Function of Ubiquitylated VP16 via RNA In Vivo
(A) Fusion of Ub to Rev.VP16 chimeras increases their activities via RNA. CAT levels for each Rev fusion protein were measured as described
in Figure 1. Middle panel presents levels of expression of our Rev fusion proteins.
(B) Rev.VP16 chimeras but not the mRev.VP16 fusion protein are ubiquitylated in vivo. Ubiquitylated Rev.VP16 was isolated with Ni2 affinity
chromatography as described in Figure 1 (lanes 1–5). The upper right panel presents inputs of Rev.VP16 and mRev.VP16 chimeras. Lower
right panel presents inputs of 6xHis.Ub fusion proteins.
(C) The Ub.mRev.VP16 chimera but not the Ub48R63R.mRev.VP16 fusion protein is highly ubiquitylated in vivo. Lanes 1–5 contain ubiquitylated
Rev-fusion proteins. Lanes 6–10 present inputs of Rev fusion proteins. Lower panel presents the input of ubiquitin.
activity on pSLIIBCAT than the parental mRev.VP16 chi- [18]. In this scenario, ubiquitylation would occur opti-
mera (Ub.mRev.VP16 and Ub4A44A.mRev.VP16, 5-fold; mally on DNA, as has been suggested for SREBP-1 [24].
Ub48R63R.mRev.VP16, 3-fold; Figure 4A, compares bars Since VP16 also contacts TRAP80 [25], which is associ-
8, 9, 10, and 11). Next, we examined if these mRevVP16 ated with Med8 [26], an E3 ligase, it is possible that this
chimeras were ubiquitylated in 293T cells. Indeed, ubiquitylation occurs after the initiation of transcription.
whereas the Ub.mRev.VP16 and Ub4A44A.mRev.VP16 This idea is supported by our observation that TRCP,
chimeras were poly-ubiquitylated (Figure 4C, compare which can ubiquitylate the Gal.VP16 chimera in cells
lanes 3 and 5), the Ub48R63R.mRev.VP16 chimera re- [27], had no activity on our Rev.VP16 fusion protein (data
mained mono-ubiquitylated (Figure 4C, lane 4). We not shown). Rather, the presence of its nucleic acid
conclude that a single ubiquitin is sufficient for optimal target, SLIIB, increased the ubiquitylation of the Rev.VP16
interactions between VP16 and P-TEFb and activity of chimera at least 10-fold (Supplementary Figure S3). In
the AAD on the elongation of transcription. Again, these this scenario, further poly-ubiquitylation of AADs would
data were confirmed by direct binding studies (Supple- occur only when P-TEFb is limiting and/or when sequen-
mental Figure S2). tial steps in transcription could not be maintained. In
Cyclin boxes in CycT1 also bind the AADs from CIITA, that case, mono-ubiquitylated AADs would no longer
cMyc, and RelA [9–11]. Not surprisingly, the AAD of VP16 be bound by P-TEFb but would now be free for further
also bound the same sequence. Since these AADs are posttranslational modifications, which would lead to the
interchangeable and they function better when ubiqui- degradation of the activators. In retrospect, this more
tylated, our findings suggest that they all bind P-TEFb
rapid degradation of AADs would then correlate with
better after this posttranslational modification. More-
their increased transcriptional activities. On the other
over, they and additional AADs have adjacent degrons,
hand, it is possible that ubiquitylation subserves twowhich facilitate their ubiquitylation [3, 20]. Better binding
functions, one the recruitment of P-TEFb for the transi-results in the optimal recruitment of P-TEFb to the tran-
tion from initiation to elongation of transcription, thescription complex, which is then modified by Cdk9. This
other for the binding of the 19S proteasome [28], whichsituation appears very analogous to late domains in ret-
could modify chromatin cotranscriptionally. Further de-roviruses that bind components of the multivesicular
tails of this mechanism await a fully reconstituted sys-body (in particular TSG101) much better when they are
tem in vitro, where effects of P-TEFb and 19S protea-ubiquitylated [21]. Indeed, this posttranslational modifi-
some can be dissected in molecular detail.cation is absolutely required for the budding and release
of HIV-1 from infected cells [22, 23]. Additionally, by
binding two different surfaces on CycT1, which have Supplemental Data
been described to inhibit each other when free in solu- Supplemental Experimental Procedures as well as two supplemen-
tion, ubiquitin and AAD are expected to improve the tal figures are available with this article online at http://www.current-
biology.com/cgi/content/full/14/12/1112/DC1.activity and possibly substrate specificity of P-TEFb
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